$EVOK
Evoke Pharma Inc

2013 Q4 Form 10-Q Financial Statement

#000119312513440287 Filed on November 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $940.0K $410.0K $140.0K
YoY Change 176.47% 192.86%
% of Gross Profit
Research & Development $636.4K $78.73K $337.0K
YoY Change 99.91% -76.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $636.4K $485.6K $477.7K
YoY Change 99.91% 1.64%
Operating Profit -$485.6K -$477.7K
YoY Change 1.64%
Interest Expense -$40.00K -$40.00K -$10.00K
YoY Change 300.0% 300.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$311.00 -$8.505K
YoY Change -96.34%
Pretax Income -$1.620M -$490.0K -$490.0K
YoY Change 141.79% 0.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.617M -$485.9K -$486.3K
YoY Change 140.42% -0.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$269.6K -$411.8K -$433.6K
COMMON SHARES
Basic Shares Outstanding 6.097M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.20M $23.74M
YoY Change
Cash & Equivalents $24.20M $23.74M $768.8K
Short-Term Investments
Other Short-Term Assets $230.0K
YoY Change
Inventory
Prepaid Expenses $234.3K
Receivables
Other Receivables
Total Short-Term Assets $24.43M $23.74M
YoY Change 20958.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $555.5K
YoY Change
Total Long-Term Assets $555.5K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $24.43M $23.74M
Total Long-Term Assets $555.5K $0.00
Total Assets $24.99M $23.74M
YoY Change 21437.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $280.0K $1.180M
YoY Change
Accrued Expenses $560.0K $390.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.443M $1.070M
YoY Change
Total Short-Term Liabilities $2.285M $2.637M
YoY Change 300.57%
LONG-TERM LIABILITIES
Long-Term Debt $1.511M $1.878M
YoY Change 54.26%
Other Long-Term Liabilities $6.830K
YoY Change
Total Long-Term Liabilities $1.518M $1.878M
YoY Change 54.96%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.285M $2.637M
Total Long-Term Liabilities $1.518M $1.878M
Total Liabilities $3.803M $4.515M
YoY Change 145.34%
SHAREHOLDERS EQUITY
Retained Earnings -$22.69M
YoY Change
Common Stock $43.87M $578.00
YoY Change 35382745.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.18M $19.22M
YoY Change
Total Liabilities & Shareholders Equity $24.99M $23.74M
YoY Change 21437.64%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$1.617M -$485.9K -$486.3K
YoY Change 140.42% -0.07%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.890M -$270.0K -$300.0K
YoY Change 190.77% -10.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.350M 22.96M 1.000M
YoY Change 2196.0%
NET CHANGE
Cash From Operating Activities -1.890M -270.0K -300.0K
Cash From Investing Activities
Cash From Financing Activities 2.350M 22.96M 1.000M
Net Change In Cash 460.0K 22.69M 700.0K
YoY Change -170.77% 3141.43%
FREE CASH FLOW
Cash From Operating Activities -$1.890M -$270.0K -$300.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71 pure
us-gaap Other Noncash Expense
OtherNoncashExpense
17446
CY2012Q3 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
1000000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1122125 shares
CY2013Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
49000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
337003
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
477749
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
24250 shares
CY2012Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
24250
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2637009
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
390981
CY2013Q1 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2000000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6096752 shares
CY2013Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
3000000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
768772
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5781752 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5781752 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
30000 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
3000000
CY2013Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1878436
CY2013Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40296800
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
19222608
CY2013Q3 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
355000
CY2013Q3 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
0
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1176226
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
578
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23738053
CY2013Q3 us-gaap Long Term Debt
LongTermDebt
2948238
CY2013Q3 us-gaap Liabilities
Liabilities
4515445
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1069802
CY2013Q3 us-gaap Assets Current
AssetsCurrent
23738053
CY2013Q3 us-gaap Assets
Assets
23738053
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23738053
CY2013Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
21074770
CY2013Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
51762
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
833751
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
865876
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1242750 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1242750 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1000000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
979792
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195525
CY2012Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
56000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
570409
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417611
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-19659354
CY2012Q4 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
2000000
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
96798
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
124
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116013
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
979792
CY2012Q4 us-gaap Liabilities
Liabilities
1550201
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
116013
CY2012Q4 us-gaap Assets
Assets
116013
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
19855003
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
20208
CY2012Q4 evok Warrant Liability
WarrantLiability
56000
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
108486 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20134968
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2500000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2426958
us-gaap Interest Income Other
InterestIncomeOther
216702
us-gaap Revenue From Grants
RevenueFromGrants
244000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20967109
us-gaap Interest Paid
InterestPaid
194626
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-107661
us-gaap Net Income Loss
NetIncomeLoss
-21074770
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
292538
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
17744041
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
469847
us-gaap Interest Expense Other
InterestExpenseOther
325512
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54264
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4005022
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43873021
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
5500000
us-gaap Share Based Compensation
ShareBasedCompensation
103592
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23738053
dei Trading Symbol
TradingSymbol
EVOK
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25204580
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16312087
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101358
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Other Noncash Expense
OtherNoncashExpense
123512
us-gaap Operating Expenses
OperatingExpenses
20967109
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
250000
evok Change In Fair Value Of Purchase Right Liability
ChangeInFairValueOfPurchaseRightLiability
188587
dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001403708
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0175 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
In addition, the number of shares of common stock available for issuance under the ESPP will be annually increased on the first day of each fiscal year during the term of the ESPP, beginning with the 2014 fiscal year, by an amount equal to the least of (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company's board of directors may determine.
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2022-06-01
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.71 pure
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
2439002 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1153751 shares
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
49000 shares
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0144 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1151002
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M7D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
105625 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> <b>Use of Estimates</b></p> <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
2426958
us-gaap Interest Income Other
InterestIncomeOther
2850
us-gaap Operating Income Loss
OperatingIncomeLoss
-1021047
us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
102125
us-gaap Interest Paid
InterestPaid
94750
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-198720
us-gaap Net Income Loss
NetIncomeLoss
-1219767
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-44562
us-gaap Interest Expense Other
InterestExpenseOther
119570
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
82000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
700489
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24773042
us-gaap Share Based Compensation
ShareBasedCompensation
13881
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23622040
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
2000000
CY2012Q2 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.0450 pure
CY2012Q2 us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P24M
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320558
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1097104
us-gaap Net Income Loss
NetIncomeLoss
-1345078
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
us-gaap Operating Expenses
OperatingExpenses
1021047
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
201666
evok Antidilutive Securities Excluded From Computation Of Earnings Per Share Number Of Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareNumberOfShares
337250 shares
evok Employee Common Stock Purchases Through Payroll Deductions Under Employee Stock Purchase Plan Price As Percentage Of Fair Market Value
EmployeeCommonStockPurchasesThroughPayrollDeductionsUnderEmployeeStockPurchasePlanPriceAsPercentageOfFairMarketValue
0.20 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2012Q3 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P10Y
us-gaap Interest Expense Other
InterestExpenseOther
10521
CY2012Q3 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2012Q3 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0143 pure
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4550
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
493210
CY2012Q3 evok Antidilutive Securities Excluded From Computation Of Earnings Per Share Number Of Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareNumberOfShares
2576252 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0175 pure
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
120625 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39459
us-gaap Interest Income Other
InterestIncomeOther
1401
us-gaap Operating Income Loss
OperatingIncomeLoss
-1340508
us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
8500
us-gaap Interest Paid
InterestPaid
4750
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4570
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
1000000
us-gaap Share Based Compensation
ShareBasedCompensation
9378
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-97104
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
847298
us-gaap Other Noncash Expense
OtherNoncashExpense
2021
us-gaap Operating Expenses
OperatingExpenses
1340508
evok Antidilutive Securities Excluded From Computation Of Earnings Per Share Number Of Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareNumberOfShares
2576252 shares
CY2012Q3 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9Y6M
CY2013Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2013Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0186 pure
CY2013Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
One-for-five
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1125875 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
116875 shares
CY2012Q3 us-gaap Interest Income Other
InterestIncomeOther
466
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-477749
CY2012Q3 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
8500
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8505
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-486254
CY2012Q3 us-gaap Interest Expense Other
InterestExpenseOther
10521
CY2012Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1550
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
485593
CY2013Q3 evok Antidilutive Securities Excluded From Computation Of Earnings Per Share Number Of Shares
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareNumberOfShares
337250 shares
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
140746
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3126
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.71 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1190212 shares
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-39000
CY2013Q3 us-gaap Interest Expense Other
InterestExpenseOther
39940
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
101875 shares
CY2013Q3 us-gaap Interest Income Other
InterestIncomeOther
629
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-485593
CY2013Q3 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
34125
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-311
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-485904
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
406862
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
7629
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78731

Files In Submission

Name View Source Status
0001193125-13-440287-index-headers.html Edgar Link pending
0001193125-13-440287-index.html Edgar Link pending
0001193125-13-440287.txt Edgar Link pending
0001193125-13-440287-xbrl.zip Edgar Link pending
d607850d10q.htm Edgar Link pending
d607850dex311.htm Edgar Link pending
d607850dex312.htm Edgar Link pending
d607850dex321.htm Edgar Link pending
d607850dex322.htm Edgar Link pending
evok-20130930.xml Edgar Link completed
evok-20130930.xsd Edgar Link pending
evok-20130930_cal.xml Edgar Link unprocessable
evok-20130930_def.xml Edgar Link unprocessable
evok-20130930_lab.xml Edgar Link unprocessable
evok-20130930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending